United States · Platforms & data · Stocktwits

MLTX Stock Climbs On Optimism Ahead Of FDA Acceptance Deadline For Lead Drug Filing

Published by Stocktwits · United States 9 h ago

Detailed summary

MoonLake is developing Sonelokimab primarily for hidradenitis suppurativa (HS), a chronic inflammatory skin condition with limited effective treatments.

Read the full article on Stocktwits Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (stocktwits.com)

Also worth reading

MarketBeat

Prediction markets tied to clinical trials and drug approvals draw lawmakers' ire

Benzinga

MLTX Stock Climbs On Optimism Ahead Of FDA Acceptance Deadline For Lead Drug Filing

Detailed summary

Share

Also worth reading

Automatic Data Processing, Inc. (NASDAQ:ADP) Plans Quarterly Dividend of $1.90

Your holiday credit-card bills are going up. What you can do to ease the pain.

Here are the major earnings before the open Thursday

AEVEX Q3 2026 slides: core business surges as Ukraine revenue fades

Prediction markets tied to clinical trials and drug approvals draw lawmakers' ire

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030